Log in

ASX:IMUImugene Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: A$0.03
50-Day Range
MA: A$0.03
52-Week Range
Now: A$0.03
Volume12.70 million shs
Average VolumeN/A
Market Capitalization$132.78 million
P/E RatioN/A
Dividend YieldN/A
Imugene Limited, an immuno-oncology biopharmaceutical company, develops mimotopes and small molecule drug candidates in Australia. Its lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu receptors, which are expressed on the surface of tumors, including gastric, breast, ovarian, and pancreatic cancers. The company's HER-Vaxx has completed a Phase I clinical trial to treat breast cancer, as well as in Phase Ib/II study for gastric cancer. It has an agreement with the Baker IDI Heart & Diabetes Institute to research, develop, and commercialize a portfolio of small molecule arginine modulators for oncology. The company is based in Carlton, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9824 5254



Sales & Book Value

Annual Sales$4.88 million
Cash FlowA$0.01 per share
Book ValueA$0.02 per share



Outstanding Shares4,425,970,176
Market Cap$132.78 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMU and its competitors with MarketBeat's FREE daily newsletter.

Imugene (ASX:IMU) Frequently Asked Questions

How has Imugene's stock been impacted by COVID-19 (Coronavirus)?

Imugene's stock was trading at A$0.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IMU shares have increased by 36.4% and is now trading at A$0.03. View which stocks have been most impacted by Coronavirus.

How were Imugene's earnings last quarter?

Imugene Limited (ASX:IMU) released its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 EPS for the quarter. View Imugene's earnings history.

Has Imugene been receiving favorable news coverage?

Media headlines about IMU stock have trended neutral this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Imugene earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Imugene.

Who are some of Imugene's key competitors?

What other stocks do shareholders of Imugene own?

Who are Imugene's key executives?

Imugene's management team includes the following people:
  • Mr. Paul Edward Alexander Hopper, Exec. Chairman (Age 63)
  • Ms. Leslie Chong, CEO, MD & Exec. Director
  • Dr. Nicholas J. Ede, Chief Technology Officer
  • Mr. Phillip Allen Hains, CFO & Joint Company Sec. (Age 60)
  • Dr. Mark T. Marino, Chief Medical Officer (Age 59)

What is Imugene's stock symbol?

Imugene trades on the ASX under the ticker symbol "IMU."

What is Imugene's stock price today?

One share of IMU stock can currently be purchased for approximately A$0.03.

How big of a company is Imugene?

Imugene has a market capitalization of $132.78 million and generates $4.88 million in revenue each year.

What is Imugene's official website?

The official website for Imugene is www.imugene.com.

How can I contact Imugene?

The company can be reached via phone at 61 3 9824 5254.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.